541 related articles for article (PubMed ID: 27135972)
1. Growth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs.
Hafner M; Niepel M; Chung M; Sorger PK
Nat Methods; 2016 Jun; 13(6):521-7. PubMed ID: 27135972
[TBL] [Abstract][Full Text] [Related]
2. Quantification of sensitivity and resistance of breast cancer cell lines to anti-cancer drugs using GR metrics.
Hafner M; Heiser LM; Williams EH; Niepel M; Wang NJ; Korkola JE; Gray JW; Sorger PK
Sci Data; 2017 Nov; 4():170166. PubMed ID: 29112189
[TBL] [Abstract][Full Text] [Related]
3. An unbiased metric of antiproliferative drug effect in vitro.
Harris LA; Frick PL; Garbett SP; Hardeman KN; Paudel BB; Lopez CF; Quaranta V; Tyson DR
Nat Methods; 2016 Jun; 13(6):497-500. PubMed ID: 27135974
[TBL] [Abstract][Full Text] [Related]
4. GRcalculator: an online tool for calculating and mining dose-response data.
Clark NA; Hafner M; Kouril M; Williams EH; Muhlich JL; Pilarczyk M; Niepel M; Sorger PK; Medvedovic M
BMC Cancer; 2017 Oct; 17(1):698. PubMed ID: 29065900
[TBL] [Abstract][Full Text] [Related]
5. Measuring Cancer Drug Sensitivity and Resistance in Cultured Cells.
Niepel M; Hafner M; Chung M; Sorger PK
Curr Protoc Chem Biol; 2017 Jun; 9(2):55-74. PubMed ID: 28628199
[TBL] [Abstract][Full Text] [Related]
6. Identification of anti-tumour biologics using primary tumour models, 3-D phenotypic screening and image-based multi-parametric profiling.
Sandercock AM; Rust S; Guillard S; Sachsenmeier KF; Holoweckyj N; Hay C; Flynn M; Huang Q; Yan K; Herpers B; Price LS; Soden J; Freeth J; Jermutus L; Hollingsworth R; Minter R
Mol Cancer; 2015 Jul; 14():147. PubMed ID: 26227951
[TBL] [Abstract][Full Text] [Related]
7. Drug design and testing: profiling of antiproliferative agents for cancer therapy using a cell-based methyl-[3H]-thymidine incorporation assay.
Griffiths M; Sundaram H
Methods Mol Biol; 2011; 731():451-65. PubMed ID: 21516428
[TBL] [Abstract][Full Text] [Related]
8. Discovery of novel CBP bromodomain inhibitors through TR-FRET-based high-throughput screening.
Zhang FC; Sun ZY; Liao LP; Zuo Y; Zhang D; Wang J; Chen YT; Xiao SH; Jiang H; Lu T; Xu P; Yue LY; Du DH; Zhang H; Liu CP; Luo C
Acta Pharmacol Sin; 2020 Feb; 41(2):286-292. PubMed ID: 31253937
[TBL] [Abstract][Full Text] [Related]
9. Differential determinants of cancer cell insensitivity to antimitotic drugs discriminated by a one-step cell imaging assay.
Tang Y; Xie T; Florian S; Moerke N; Shamu C; Benes C; Mitchison TJ
J Biomol Screen; 2013 Oct; 18(9):1062-71. PubMed ID: 23788527
[TBL] [Abstract][Full Text] [Related]
10. A simple high-content cell cycle assay reveals frequent discrepancies between cell number and ATP and MTS proliferation assays.
Chan GK; Kleinheinz TL; Peterson D; Moffat JG
PLoS One; 2013; 8(5):e63583. PubMed ID: 23691072
[TBL] [Abstract][Full Text] [Related]
11. Structure-based discovery of potent and selective small-molecule inhibitors targeting signal transducer and activator of transcription 3 (STAT3).
Huang Q; Zhong Y; Li B; Ouyang S; Deng L; Mo J; Shi S; Lv N; Wu R; Liu P; Hu W; Zhang X; Wang Y
Eur J Med Chem; 2021 Oct; 221():113525. PubMed ID: 34000483
[TBL] [Abstract][Full Text] [Related]
12. Optimization of Cell Viability Assays for Drug Sensitivity Screens.
Larsson P; Parris TZ
Methods Mol Biol; 2023; 2644():287-302. PubMed ID: 37142929
[TBL] [Abstract][Full Text] [Related]
13. Identification of novel gankyrin binding scaffolds by high throughput virtual screening.
Kanabar D; Kabir A; Chavan T; Kong J; Yoganathan S; Muth A
Bioorg Med Chem Lett; 2021 Jul; 43():128043. PubMed ID: 33865970
[No Abstract] [Full Text] [Related]
14. Screening Library Design.
Ashenden SK
Methods Enzymol; 2018; 610():73-96. PubMed ID: 30390806
[TBL] [Abstract][Full Text] [Related]
15. The RNA disruption assay is superior to conventional drug sensitivity assays in detecting cytotoxic drugs.
Mapletoft JPJ; St-Onge RJ; Guo B; Butler P; Masilamani TJ; D'costa L; Pritzker LB; Parissenti AM
Sci Rep; 2020 May; 10(1):8671. PubMed ID: 32457334
[TBL] [Abstract][Full Text] [Related]
16. Upscaling of hiPS Cell-Derived Neurons for High-Throughput Screening.
Traub S; Stahl H; Rosenbrock H; Simon E; Heilker R
SLAS Discov; 2017 Mar; 22(3):274-286. PubMed ID: 28231034
[TBL] [Abstract][Full Text] [Related]
17. Establishing a high-throughput and automated cancer cell proliferation panel for oncology lead optimization.
Lei M; Ribeiro H; Kolodin G; Gill J; Wang YS; Maloney D; Fan Y; Li S; Myer L; Beluch M; Zhang L; Schweizer L
J Biomol Screen; 2013 Oct; 18(9):1043-53. PubMed ID: 23733846
[TBL] [Abstract][Full Text] [Related]
18. Drug Repurposing Screen Identifies Novel Classes of Drugs with Anticancer Activity in Mantle Cell Lymphoma.
Han C; Yu X; Zhang C; Cai Y; Cao Y; Wang S; Shen J
Comb Chem High Throughput Screen; 2019; 22(7):483-495. PubMed ID: 31526347
[TBL] [Abstract][Full Text] [Related]
19. Natural products as leads for anticancer drug discovery: discovery of new chemotypes of microtubule stabilizers through reengineering of the epothilone scaffold.
Altmann KH; Cachoux F; Feyen F; Gertsch J; Kuzniewski CN; Wartmann M
Chimia (Aarau); 2010; 64(1-2):8-13. PubMed ID: 21137676
[TBL] [Abstract][Full Text] [Related]
20. Novel Small Molecule Inhibitors of Choline Kinase Identified by Fragment-Based Drug Discovery.
Zech SG; Kohlmann A; Zhou T; Li F; Squillace RM; Parillon LE; Greenfield MT; Miller DP; Qi J; Thomas RM; Wang Y; Xu Y; Miret JJ; Shakespeare WC; Zhu X; Dalgarno DC
J Med Chem; 2016 Jan; 59(2):671-86. PubMed ID: 26700752
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
